Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress Across Its Cardiovascular Gene Therapy Pipeline
Rocket Pharmaceuticals, Inc., a fully integrated, commercial-stage biotechnology company focused on developing genetic medicines for rare and life-threatening diseases, has announced its financial results for the third quarter ended September 30, 2026. Alongside its financial performance, the company provided updates on its clinical development programs, regulatory progress, commercial preparations and strategic financing activities, highlighting continued advancement across its portfolio of genetic therapies, particularly for inherited cardiovascular disorders.
During the third quarter and subsequent weeks, Rocket achieved several important milestones across its cardiovascular pipeline. These included receiving alignment from the U.S. Food and Drug Administration (FDA) on key elements of the pivotal Phase 2 clinical trial of RP-A501 for Danon disease, initiating dosing in the Phase 1 study of RP-A701 for BAG3-associated dilated cardiomyopathy (BAG3-DCM), and continuing clinical and regulatory discussions concerning RP-A601 for PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM).
The company also reported commercial readiness for KRESLADI™ (marnetegragene autotemcel), including the activation of its first Qualified Treatment Centers, and secured a strategic credit facility of up to $150 million from Hercules Capital, Inc. to support its clinical and commercial priorities.
Commenting on the company’s progress, Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals, emphasized the importance of completing dosing in the pivotal RP-A501 study by mid-2027. He noted that the company is also advancing its broader cardiovascular portfolio through the initiation of the RP-A701 Phase 1 trial and continued FDA engagement regarding the potential pivotal development of RP-A601.
Dr. Shah further highlighted the progress made toward the commercial introduction of KRESLADI, with the activation of the first Qualified Treatment Centers representing an important step toward providing treatment to eligible pediatric patients. He added that Rocket’s financial resources, combined with the additional flexibility provided by the Hercules credit facility, are expected to support the execution of its clinical development plans and upcoming commercial milestones.
FDA Alignment Supports Advancement of RP-A501 Pivotal Phase 2 Trial in Danon Disease
One of Rocket Pharmaceuticals’ most significant recent developments is the regulatory progress of RP-A501, its investigational gene therapy being developed for Danon disease, a rare genetic disorder associated with severe cardiac complications and other multisystem manifestations.
On September 15, 2026, Rocket announced that it had reached alignment with the FDA on continued enrollment and dosing, as well as several important design elements of the global pivotal Phase 2 clinical trial evaluating RP-A501 in patients with Danon disease.
The regulatory alignment covers the recalibrated dose, a 12-patient pivotal efficacy population and the establishment of 12-month co-primary endpoints. These agreements provide greater clarity regarding the clinical development strategy and the evidence required to support a potential accelerated approval pathway.
Importantly, the first three patients treated under the modified clinical trial protocol will count toward the 12-patient pivotal efficacy population. This approach allows the company to incorporate patients already treated under the revised protocol into the pivotal assessment.
At the 12-month evaluation, at least seven of the 12 patients must demonstrate improvements across both co-primary endpoints to meet the established pivotal efficacy success criterion.
The first endpoint requires evidence of myocardial LAMP2 expression at Grade 1 or higher. The second endpoint requires a reduction of at least 10% from baseline in left ventricular mass index (LVMI). Together, these measures are intended to evaluate the biological activity of RP-A501 and its potential impact on cardiac disease manifestations.
The company believes that these endpoints will provide important clinical evidence regarding the treatment’s ability to address the underlying disease mechanism and improve relevant cardiac measures.
On October 6, 2026, Rocket hosted an investor webinar to provide additional information about RP-A501’s development program. The presentation included updated longer-term follow-up findings from the Phase 1 study, key clinical development milestones and initial safety observations from the first three patients treated under the modified protocol.
The company reported encouraging initial safety observations in these patients, supporting continued evaluation of the revised dosing approach. The updated information also provided additional context regarding the potential clinical development opportunity for RP-A501.
During the webinar, Rocket discussed updated epidemiological assessments of Danon disease. Independent genotype-based and phenotype-based analyses estimated that approximately 10,000 to 11,000 people may be living with Danon disease in the United States, including approximately 4,000 males.
Rocket has identified more than 900 individuals with Danon disease, demonstrating the company’s efforts to improve disease identification and understand the potential patient population.
However, the company noted that prevalence estimates may include individuals who remain undiagnosed or asymptomatic. Therefore, the estimated population should not be interpreted as the number of patients who would necessarily qualify for treatment.
Looking ahead, Rocket expects to complete dosing in the pivotal Phase 2 trial by mid-2027, with topline clinical results anticipated in mid-2028. These milestones represent important steps toward determining the potential role of RP-A501 in treating patients with Danon disease.
RP-A601 Development Continues for PKP2-Associated Arrhythmogenic Cardiomyopathy
Rocket Pharmaceuticals is also continuing to advance RP-A601, its investigational genetic medicine being developed for PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM).
PKP2-ACM is an inherited cardiovascular disorder associated with abnormalities in the heart’s structural and electrical functions. The disease can lead to serious cardiac complications, including potentially life-threatening ventricular arrhythmias and progressive deterioration of right ventricular function.
The RP-A601 program is designed to address the underlying genetic cause of the condition by targeting the protein abnormalities associated with PKP2 deficiency.
Rocket continues to evaluate RP-A601 through its ongoing Phase 1 clinical study while engaging with the FDA regarding the next stage of clinical development and the potential design of a pivotal study.
Previously reported Phase 1 findings demonstrated increased PKP2 protein expression and improved desmosomal localization. Desmosomes are specialized structures that help maintain connections between heart muscle cells and support the structural integrity of cardiac tissue.
The study also demonstrated directional improvements in measures of arrhythmia and right ventricular function. These observations provide preliminary evidence of biological activity and support continued investigation of RP-A601.
The ongoing Phase 1 study remains open and actively enrolling patients. Continued enrollment is expected to help Rocket characterize the therapy’s biological activity across a broader range of disease severity and generate additional information to guide future clinical development.
The company plans to provide further clinical and regulatory updates as the program advances.
Additional information about the RP-A601 Phase 1 clinical trial is available through ClinicalTrials.gov under identifier NCT05885412.
RP-A701 Phase 1 Trial Begins Dosing for BAG3-Associated Dilated Cardiomyopathy
Rocket Pharmaceuticals has achieved another clinical milestone with the initiation of dosing in the Phase 1 clinical trial of RP-A701, its investigational gene therapy for BAG3-associated dilated cardiomyopathy (BAG3-DCM).
BAG3-DCM is a genetic cardiovascular condition associated with mutations in the BAG3 gene, which plays an important role in maintaining the health and function of heart muscle cells. Disruptions in BAG3 function can contribute to progressive cardiac dysfunction and dilated cardiomyopathy.
The initiation of dosing represents an important expansion of Rocket’s cardiovascular development portfolio and demonstrates continued investment in genetic medicines targeting inherited heart diseases.
The multicenter, dose-escalation Phase 1 study is designed to assess the safety and biological activity of RP-A701 in adults with BAG3-DCM. The trial will also evaluate preliminary evidence of clinical efficacy and help determine the appropriate dose for further development.
As an early-stage clinical study, the trial is expected to generate important information about the treatment’s safety profile, tolerability and potential biological effects in patients with the condition.
In addition to initiating clinical dosing, Rocket achieved an important regulatory milestone in Europe. On October 20, 2026, the European Commission granted orphan designation to RP-A701 for the treatment of BAG3-DCM.
Orphan designation is intended to encourage the development of treatments for rare diseases by providing eligible medicines with regulatory and development incentives. The designation recognizes the potential importance of advancing new therapeutic approaches for conditions affecting relatively small patient populations with significant unmet medical needs.
The Phase 1 study of RP-A701 is registered on ClinicalTrials.gov under identifier NCT07137338.
KRESLADI Achieves Commercial Readiness With First Qualified Treatment Centers Activated
Beyond its investigational cardiovascular pipeline, Rocket Pharmaceuticals is progressing toward the commercial delivery of KRESLADI™ (marnetegragene autotemcel).
On October 1, 2026, the company achieved commercial readiness for KRESLADI, marking an important operational milestone in its efforts to prepare for patient access.
As part of this progress, Rocket confirmed that two Qualified Treatment Centers have been activated and are ready to begin commercial patient onboarding. The company has also established its external manufacturing network to support the treatment’s commercial operations.
The activation of Qualified Treatment Centers is an essential component of the commercialization process for advanced genetic medicines. These specialized centers provide the infrastructure and clinical expertise required to coordinate patient evaluation, treatment administration and associated care.
Establishing an external manufacturing network is similarly important because advanced cell and gene therapies require specialized production capabilities, quality controls and coordinated logistics.
Rocket’s commercial readiness milestone reflects progress across these operational requirements and brings the company closer to making KRESLADI available to eligible children.
The activation of the first two treatment centers provides an initial foundation for commercial patient onboarding. The company will continue working to coordinate its treatment-center network and manufacturing capabilities as it advances its commercial activities.
Hercules Capital Credit Facility Provides Access to Up to $150 Million
To strengthen its financial flexibility and support ongoing clinical and commercial activities, Rocket Pharmaceuticals announced a strategic credit facility agreement with Hercules Capital, Inc. on October 6, 2026.
The agreement provides access to up to $150 million in potential financing, which is intended to support execution of the pivotal Phase 2 trial of RP-A501 and continued advancement of the company’s broader cardiovascular gene therapy portfolio.
Under the terms of the agreement, Rocket received $35 million at closing. The company may also draw an additional $35 million at its option during specified periods, subject to the agreement’s terms and conditions.
An additional $30 million may become available following achievement of a specified clinical milestone in the Danon disease program.
The remaining $50 million is subject to approval by Hercules Capital’s investment committee.
The financing arrangement provides Rocket with additional capital flexibility as it progresses through several important clinical development milestones. In particular, the funding is expected to support the continued execution of the RP-A501 pivotal study while maintaining resources for the advancement of RP-A601 and RP-A701.
The facility also complements the company’s existing cash and investment position, providing additional financial options as it works toward its anticipated clinical and commercial objectives.
Third Quarter 2026 Financial Performance
Rocket Pharmaceuticals reported cash, cash equivalents and investments totaling $279.4 million as of September 30, 2026.
The company’s financial results for the third quarter reflected changes in research and development spending, general and administrative expenses, other income and net loss compared with the corresponding period in 2025.
Research and Development Expenses
Research and development expenses were $31.2 million for the three months ended September 30, 2026, compared with $34.1 million during the same period in 2025.
This represented a decrease of $2.9 million year over year.
The reduction was primarily driven by a $3.5 million decrease in stock-based compensation, other compensation and employee benefit expenses, reflecting a reduction in research and development headcount.
The company also recorded a $1.9 million decrease in manufacturing and development expenses and direct material costs. Depreciation expenses declined by $1.2 million, primarily due to a decrease in the company’s asset base.
These cost reductions were partially offset by higher spending in several areas. Laboratory-related expenses increased by $1.4 million, while professional fees also increased by $1.4 million. Clinical trial expenses increased by an additional $0.6 million.
The changes reflect the company’s evolving research and development spending requirements as it continues to advance its clinical programs and manage its operational resources.
General and Administrative Expenses
General and administrative expenses increased to $19.8 million in the third quarter of 2026, compared with $18.4 million in the third quarter of 2025.
The increase of $1.4 million was primarily attributable to higher post-marketing commitment expenses, which increased by $3.4 million, along with a $0.6 million increase in commercial preparation-related expenses.
These increases were partially offset by a $2.2 million reduction in stock-based compensation, other compensation and employee benefit expenses due to decreased general and administrative headcount.
Legal expenses also declined by $0.6 million compared with the corresponding quarter of the previous year.
The increase in administrative spending reflects certain ongoing commitments and commercial preparation activities as Rocket continues to advance its product-related operations.
Other Income
Other income totaled $1.8 million for the three months ended September 30, 2026, compared with $1.9 million in the corresponding period of 2025.
The $0.1 million decrease was primarily driven by a $0.4 million reduction in the accretion of discount on investments, net. This was partially offset by a $0.3 million increase in interest income.
Income Taxes
Rocket reported income tax expenses of $0.1 million for the third quarter of 2026, compared with no income tax expenses during the same period in 2025.
The change was attributable to an adjustment in the company’s estimated income taxes payable during the three months ended September 30, 2026.
Net Loss and Loss Per Share
Rocket Pharmaceuticals reported a net loss of $49.2 million for the third quarter of 2026, equivalent to a basic and diluted loss of $0.43 per share.
This compared with a net loss of $50.3 million, or $0.45 per basic and diluted share, during the third quarter of 2025.
The year-over-year comparison reflects a modest reduction in the company’s quarterly net loss.
As of September 30, 2026, Rocket Pharmaceuticals had 111,386,536 shares of common stock outstanding.
Financial Outlook and Cash Runway
Rocket Pharmaceuticals ended the third quarter of 2026 with $279.4 million in cash, cash equivalents and investments.
Based on its current operating plan, the company expects its cash, cash equivalents and investments as of September 30, 2026, to be sufficient to fund operations into the third quarter of 2028.
This projected cash runway provides financial visibility as Rocket works toward several significant milestones across its clinical and commercial portfolio.
Key anticipated activities include completing dosing in the pivotal RP-A501 Phase 2 trial by mid-2027, generating topline results from the study in mid-2028, continuing clinical development of RP-A601 and RP-A701, and progressing commercial patient onboarding for KRESLADI.
The additional financing flexibility provided by the Hercules Capital facility may further support the company’s ability to execute its development strategy, subject to the applicable funding conditions.
Advancing a Broad Portfolio of Genetic Medicines for Rare Diseases
Rocket Pharmaceuticals’ third-quarter 2026 results highlight continued progress across its clinical pipeline, regulatory activities and commercial operations.
The company’s cardiovascular strategy remains centered on advancing genetic medicines for inherited disorders with significant unmet medical needs. RP-A501 for Danon disease, RP-A601 for PKP2-ACM and RP-A701 for BAG3-DCM represent three important programs within this strategy, each targeting a distinct genetic cause of cardiovascular disease.
The FDA alignment for RP-A501 provides a clearer pathway for completing its pivotal Phase 2 study, while the ongoing development of RP-A601 and the initiation of RP-A701 dosing demonstrate the company’s efforts to expand its cardiovascular portfolio.
At the same time, achieving commercial readiness for KRESLADI and activating the first two Qualified Treatment Centers represent important operational progress toward patient access.
With $279.4 million in cash, cash equivalents and investments at the end of September 2026, an expected cash runway into the third quarter of 2028 and access to a potential $150 million Hercules credit facility, Rocket is positioning itself to pursue its upcoming clinical and commercial objectives.
As the company moves into the next phase of development, investors and the rare disease community will be watching for additional clinical data, regulatory milestones and progress toward commercial patient treatment.
About KRESLADI™
KRESLADI™ (marnetegragene autotemcel) is an autologous hematopoietic stem cell-based gene therapy designed to address the underlying genetic cause of severe leukocyte adhesion deficiency-I (LAD-I), an ultra-rare, life-threatening pediatric immunodeficiency. The therapy utilizes ex vivo lentiviral vector-mediated gene transfer to introduce a functional copy of the ITGB2 gene into a patient’s hematopoietic stem cells, enabling expression of CD18 and restoration of leukocyte adhesion and migration.
KRESLADI is administered as a one-time intravenous infusion following myeloablative conditioning. In clinical studies, treatment with KRESLADI resulted in increased neutrophil CD18 and CD11a surface expression, supporting the biological activity of the therapy and forming the basis for accelerated approval. Continued approval may be contingent upon verification and description of clinical benefit through ongoing clinical follow-up and additional post-marketing data collection.
Severe LAD-I is characterized by recurrent, serious bacterial and fungal infections beginning in early infancy and is associated with high early-childhood mortality without effective treatment.